Form 4: Exelixis Director Tomas Heyman Receives Equity Grant of 9,812 Restricted Stock Units

Exelixis, Inc. Director Tomas J. Heyman was granted 9,812 restricted stock units (RSUs) on May 29, 2025, which are set to vest fully on May 29, 2026.

Summary

• Tomas J. Heyman, a Director of Exelixis, Inc. (EXEL), acquired 9,812 shares of Common Stock in the form of Restricted Stock Units (RSUs) on May 29, 2025.
• The RSUs were granted under the Exelixis, Inc. 2017 Equity Incentive Plan.
• Each RSU is economically equivalent to one share of Exelixis, Inc. common stock.
• The RSUs will vest 100% on May 29, 2026, contingent upon Mr. Heyman's continuous service to the company through that date.
• Following this transaction, Mr. Heyman beneficially owns 42,282 shares of Common Stock, which includes these newly acquired RSUs and previously held RSUs that are yet to vest.

Sentiment

Score: 7

Explanation: The sentiment is positive as the RSU grant aligns the director's interests with shareholders, indicating continued commitment. However, it is a routine compensation event and not indicative of significant operational or financial news.

Positives

• The grant of restricted stock units aligns the director's financial interests with those of the shareholders, promoting long-term commitment and performance.
• Equity compensation is a standard practice for retaining and incentivizing key personnel, including directors.

Future Outlook

The document indicates a future vesting event for the granted restricted stock units on May 29, 2026, contingent on the director's continuous service.

Industry Context

The granting of restricted stock units to directors is a common and widely accepted practice in the biotechnology and pharmaceutical industries, serving as a key component of executive and director compensation packages to align interests with long-term company performance.

Comparison to Industry Standards

• The RSU grant to a director is consistent with typical equity compensation practices observed across publicly traded companies in the biotechnology sector, such as Amgen Inc. or Gilead Sciences, Inc., which frequently utilize RSUs to incentivize and retain board members.
• The vesting schedule of 100% after one year is a common structure for director equity grants, aiming to provide immediate alignment while ensuring continued service.

Related Party Transactions

• The grant of restricted stock units to Tomas J. Heyman, a director, constitutes a related party transaction as it involves compensation from the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's long-term interests with those of the shareholders, potentially leading to more shareholder-friendly decisions.
• Employees: This specific filing does not directly impact general employees, but it reflects the company's compensation philosophy for its leadership.

Next Steps

• The granted RSUs are scheduled to vest on May 29, 2026, subject to the director's continuous service.

Key Dates

Recommendation

Keywords

Exelixis, EXEL, Form 4, Restricted Stock Units, RSU, Director Compensation, Equity Grant, Insider Transaction, Beneficial Ownership